Heart failure & cardiomyopathiesCohort study
Epidemiological trends in hypertrophic cardiomyopathy in adults—a Swedish nationwide registry study
- Nationwide registry study
Authors' conclusion
Between 2003 and 2022, the prevalence of oHCM nearly quadrupled, while nHCM increased more than six-fold. Contributing factors include a nearly doubled incidence, primarily driven by a rise in nHCM, and halved all-cause mortality. These trends were most pronounced in older adults, consistent with increased detection of individuals with milder phenotypes.
Study context
- Population
- Adults 17–85 years diagnosed with hypertrophic cardiomyopathy (HCM) in inpatient or specialized outpatient care, Swedish National Patient Register, 2003–202267% nHCM
- Participants
- 11,299 adults
- Exposure
- oHCM vs nHCM; trends 2003–2022
- Outcome
- Annual age- and sex-adjusted incidence, prevalence and all-cause mortality
- Follow-up
- 2003–2022
Main finding
As reported in the abstract
Overall prevalence increased (per 100,000 populations)
14 to 73
Incidence increased (per 100,000 person-years), largely due to nHCM, steepest among middle-aged and older adults
5.1 to 9.3
Annual all-cause mortality declined, similar for nHCM and oHCM at study end
9.8% to 4.3%
Observational data: associations, not effects.
Further findings
Prognosis by age group
- Prognosis improved across all age groups, most notably among older age groups
Original publication
Summarised from the published abstract; every number is checked against it